Company / R&D Expense
NextCure, Inc. R&D Expense History
FY2019-FY2021 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$46.6M
FY2021
5-year range
$19.8M / $46.6M
FY2019-FY2021
Trend
+36.1%
vs FY2020
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $20M to $47M over the past 2 years.
Based on SEC 10-K filings.
$47M in FY2021.
Improved from $20M to $47M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2021, r&d expense increased 36.1% year-over-year.
Company context
Key Data Points
- Altman Z-Score -2.19 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2021 | $46.6M | +36.1% |
| FY2020 | $34.2M | +72.9% |
| FY2019 | $19.8M | - |
As of FY2021 · SEC 10-K Annual Filings · Updated Jun 28, 2026